Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial

Peer Review reports

Original Submission
5 Sep 2019	Submitted	Original manuscript
21 Nov 2019	Reviewed	Reviewer Report - Masataka Sawaki
14 May 2020	Reviewed	Reviewer Report
19 Jun 2020	Author responded	Author comments - Changjun Wang
Resubmission - Version 2
19 Jun 2020	Submitted	Manuscript version 2
3 Jul 2020	Author responded	Author comments - Changjun Wang
Resubmission - Version 3
3 Jul 2020	Submitted	Manuscript version 3
Publishing
7 Jul 2020	Editorially accepted
13 Jul 2020	Article published	10.1186/s12885-020-07143-2

Back to article page